NASDAQ:TELA TELA Bio (TELA) Stock Price, News & Analysis $2.65 +0.16 (+6.43%) (As of 10/23/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About TELA Bio Stock (NASDAQ:TELA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get TELA Bio alerts:Sign Up Key Stats Today's Range$2.53▼$3.0550-Day Range$2.32▼$3.1152-Week Range$2.30▼$7.84Volume2.56 million shsAverage Volume183,127 shsMarket Capitalization$65.34 millionP/E RatioN/ADividend YieldN/APrice Target$10.00Consensus RatingBuy Company OverviewTELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.Read More… Watch this before it gets removed (Ad)If you missed it, my emergency election broadcast is now available - but will be removed soonClick here to watch it now. TELA Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreTELA MarketRank™: TELA Bio scored higher than 47% of companies evaluated by MarketBeat, and ranked 613th out of 1,001 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTELA Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTELA Bio has only been the subject of 4 research reports in the past 90 days.Read more about TELA Bio's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for TELA Bio are expected to grow in the coming year, from ($1.39) to ($1.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of TELA Bio is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of TELA Bio is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTELA Bio has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about TELA Bio's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.65% of the outstanding shares of TELA Bio have been sold short.Short Interest Ratio / Days to CoverTELA Bio has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in TELA Bio has recently decreased by 3.53%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTELA Bio does not currently pay a dividend.Dividend GrowthTELA Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted6.65% of the outstanding shares of TELA Bio have been sold short.Short Interest Ratio / Days to CoverTELA Bio has a short interest ratio ("days to cover") of 8.1.Change versus previous monthShort interest in TELA Bio has recently decreased by 3.53%, indicating that investor sentiment is improving. News and Social Media1.9 / 5News Sentiment0.35 News SentimentTELA Bio has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for TELA Bio this week, compared to 2 articles on an average week. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, TELA Bio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.00% of the stock of TELA Bio is held by insiders.Percentage Held by Institutions94.35% of the stock of TELA Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about TELA Bio's insider trading history. Receive TELA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for TELA Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TELA Stock News HeadlinesTELA Bio (TELA) Gets a Buy from Piper SandlerOctober 24 at 3:41 AM | markets.businessinsider.comTela Bio 12M share Spot Secondary priced at $2.25October 24 at 3:41 AM | markets.businessinsider.comWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonOctober 24, 2024 | Porter & Company (Ad)TELA Bio Announces Pricing of Public Offering of Common Stock and Pre-Funded WarrantsOctober 23 at 8:07 AM | globenewswire.comTELA Bio (NASDAQ:TELA) Stock, Short Interest ReportOctober 23 at 3:09 AM | benzinga.comTELA Bio Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsOctober 22 at 4:05 PM | globenewswire.comGet Ready: TELA Bio to Unveil Q3 2024 Financial Results on November 7!October 18, 2024 | msn.comTELA Bio to Announce Third Quarter 2024 Financial ResultsOctober 17, 2024 | globenewswire.comSee More Headlines TELA Stock Analysis - Frequently Asked Questions How have TELA shares performed this year? TELA Bio's stock was trading at $6.62 at the start of the year. Since then, TELA stock has decreased by 60.0% and is now trading at $2.65. View the best growth stocks for 2024 here. How were TELA Bio's earnings last quarter? TELA Bio, Inc. (NASDAQ:TELA) announced its quarterly earnings results on Monday, August, 12th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.06. The business had revenue of $16.09 million for the quarter, compared to analyst estimates of $19 million. TELA Bio had a negative trailing twelve-month return on equity of 252.57% and a negative net margin of 65.04%. When did TELA Bio IPO? TELA Bio (TELA) raised $60 million in an IPO on Friday, November 8th 2019. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers. Who are TELA Bio's major shareholders? Top institutional shareholders of TELA Bio include Embree Financial Group (0.04%). Insiders that own company stock include Ew Healthcare Partners Fund 2,, Orbimed Advisors Llc, Opaleye Management Inc, Antony Koblish, Roberto Cuca and Gregory A Firestone. View institutional ownership trends. How do I buy shares of TELA Bio? Shares of TELA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of TELA Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that TELA Bio investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), JPMorgan Chase & Co. (JPM), Netflix (NFLX) and Chevron (CVX). Company Calendar Last Earnings8/12/2024Today10/23/2024Next Earnings (Confirmed)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNASDAQ:TELA CUSIPN/A CIK1561921 Webwww.telabio.com Phone484-320-2930FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$12.00 Low Stock Price Target$8.00 Potential Upside/Downside+277.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.67) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-46,660,000.00 Net Margins-65.04% Pretax Margin-65.04% Return on Equity-252.57% Return on Assets-56.63% Debt Debt-to-Equity Ratio14.22 Current Ratio3.41 Quick Ratio2.52 Sales & Book Value Annual Sales$64.74 million Price / Sales1.01 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book3.44Miscellaneous Outstanding Shares24,655,000Free Float23,231,000Market Cap$65.34 million OptionableOptionable Beta0.99 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:TELA) was last updated on 10/24/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMusk warns humanity: “Obsolete”The 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWatch this before it gets removed If you missed it, my emergency election broadcast is now available - but will be removed soonPorter & Company | Sponsored #1 Pre-IPO Opportunity For 2024 [Take Action Now!]According to James, the largest IPO in history could kick off in a matter of weeks. I’m talking about Starl...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredGoldman Sachs’ AI warningAfter warning of last year's historic bank run, weeks in advance... Legendary stock-picker Marc Chaikin jus...Chaikin Analytics | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding TELA Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share TELA Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.